WITHDRAWN: Enabling infrastructure for global health product development.

Drug Discov Today

3040 Cornwallis Road, Research Triangle Park, NC 27709, USA.

Published: June 2012

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2012.05.014DOI Listing

Publication Analysis

Top Keywords

withdrawn enabling
4
enabling infrastructure
4
infrastructure global
4
global health
4
health product
4
product development
4
development article
4
article withdrawn
4
withdrawn request
4
request authors
4

Similar Publications

The β-amyloid precursor protein-cleaving enzyme 1 (BACE1) inhibitor JNJ-54861911, a candidate for the treatment of Alzheimer's disease, was withdrawn from clinical trials due to drug-induced liver injury (DILI). This paper describes our investigation of the metabolism of JNJ-54861911 to understand the potential contribution to the observed DILI. In human hepatocytes, JNJ-54861911 is metabolized by CYP450 3A4 to a reactive intermediate (RI), which undergoes glutathione (GSH) addition at C6 of the 2-amino-4-methyl-1,3-thiazin-4-yl moiety via glutathione S-transferase α1 (GSTA1) catalysis.

View Article and Find Full Text PDF

A method to evaluate enhanced rock weathering using intact soil monoliths under field conditions.

MethodsX

December 2024

School of Natural and Environmental Sciences, Newcastle University, Kings Road, Newcastle upon Tyne, England NE1 7RU, United Kingdom.

Article Synopsis
  • * The study presents a method to install and extract soil monoliths using buried PVC pipes, which allows for the collection of soil water samples without external interference.
  • * Through a 6-month trial with 36 monoliths, the method proved reliable for analyzing leachate, contributing to the validation of ERW's ability to remove carbon dioxide effectively.
View Article and Find Full Text PDF

Toward better cures for lung disease.

Clin Microbiol Rev

December 2024

Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.

SUMMARYThe opportunistic pathogen (Mab) causes fatal lung infections that bear similarities-and notable differences-with tuberculosis (TB) pulmonary disease. In contrast to TB, no antibiotic is formally approved to treat Mab disease, there is no reliable cure, and the discovery and development pipeline is incredibly thin. Here, we discuss the factors behind the unsatisfactory cure rates of Mab disease, namely intrinsic resistance and persistence of the pathogen, and the use of underperforming, often parenteral and toxic, repurposed drugs.

View Article and Find Full Text PDF

Enterolactone, coumaric acid and vitexin are polyphenolic compounds present in a variety of fruits, vegetables, cereals and plants. These bioactive compounds are in high demand due to their antioxidant property in various tissues and organs. The purpose of this study was to develop a simultaneous extraction method, an aqueous two-phase extraction (ATPE) method, that would enable the extraction of these compounds from .

View Article and Find Full Text PDF

Unlabelled: Clinical trials, by contributing to the development of diagnostics and to the search for modern, more effective, and safer therapies, have become one of the most important elements of the healthcare system. They enable the introduction of innovative drugs and treatments that can significantly improve patients' quality of life. Not only does this research help to understand disease mechanisms, but it also enables the personalization of therapy, which often increases the effectiveness of treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!